-
Kai Widdrington Withdraws from Strictly Come Dancing Due to Illness; Aljaž Škorjanec Steps In
-
Amr Diab Announces First London Headline Show at The O2 in December 2026
-
Henan Grave Carved with Herbal Prescriptions Draws Hundreds of Visitors Daily
-
Masdar Completes $950M Lockhart Solar and Storage Project in California
-
USMNT Coaching Search: Guardiola, Cherundolo, and Others Named as Pochettino Replacements
-
Mansa’s AI Microdrama Sparks Debate Over Black Representation in Hollywood
-
SDF Intelligence Unit Avoided Classifying Civilian Data as Public Records
-
Microsoft Outage Disrupts Outlook and Teams for Hours Globally
-
Inflation Breach and Bond Yields Spark Rate Hike Fears for December
-
RSC’s ‘Julius Caesar’ Reimagined in Women’s Prison Setting for School Tour
-
Documentary Reveals How Screams Exposed Alleged Camgirl Exploitation Ring
-
Korea Reviews GLP-1 Vision Loss Warnings Following US FDA Action
-
Jane Maciver Joins Fragrance Creators Board
-
Vulcan Minerals Inc. - Review and Update on Affiliated Company Atlas Salt Inc.
-
The Epomaker Alice40 Brings Mahjong Sound and Sunset Style to Ergonomic Typing
-
SMX Brings American Ingenuity to the Next Frontier of Artificial Intelligence
-
Road Access Completed Drill Program to Begin
-
ACCESS Newswire Continues to Repurchase its Shares
-
Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
-
Jaguar Health to Hold Investor Webcast November 17 Regarding Q3 2026 Financials & Corporate Updates
-
Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
-
Does IRS Debt Expire? Clear Start Tax Explains the 10-Year Collection Statute and What Quietly Resets It
-
GameSquare's Hatchet Publishes TikTok Live for Gaming in H1 2026 Report
-
Arrive AI Reports Third Quarter 2026 Results Highlighted by Revenue Growth and Expanded Partnerships
-
Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q2
-
Mako Mining Reports Q3 2026 Financial Results, Including Adjusted EBITDA(1) of US$30.3 million and EPS of US$0.19/share
-
eXoZymes to Host Third Quarter 2026 update Conference Call on Thursday, November 19, 2026
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 13
-
How Families Plan and Save for Holiday Travel
-
DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
-
Phoenix ABA Therapy Provider Action Behavior Centers Delivers Largest Donation in Jose's Closet History During Second Arizona Hands In Week
-
Matt Hagan Is One Race Away from NHRA History on FOX Sports' FS1 as American Rebel Light Beer Rallies Fans Behind Tony Stewart Racing - Win Hagan Win!
-
U.S. Export-Import Bank Features NioCorp's Elk Creek Critical Minerals Project in EXIM's Factory Floor Fridays Initiative
-
MEDIA ALERT: SMX Draws Widespread Media Attention Across National, Business and Technology Publications
-
A Domestic Lithium Frontier: ELEKTROS Advances Review of Northern New York Opportunity
-
PP Teck Announces Launch Week Dealer Terms: Free Pallet of Polymer and 20% Off Equipment for Businesses That Sign Nov. 16-20
-
Positioning For America's Lithium Future: ELEKTROS Evaluates Northern New York Opportunity
-
Exploring a New U.S. Lithium Pathway: ELEKTROS Continues Review of Northern New York Opportunity
-
Sparta Capital Ltd. Announces Application to the Ontario Securities Commission to Become a Reporting Issuer in Ontario
-
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026
-
Rifstone Capital LLC Advances Institutional Research Platform with Expanded Global Allocation Framework
-
SMX Puts American Innovation to Work in the New Era of Artificial Intelligence
-
Sekur Private Data Raises SekurOne Price 25% to US$3,750 Per Year
-
Foundation Software Explores How Contractors Can Prepare for the AI-Driven Construction Boom
-
Trustpoint Xposure Launches Program to Help Startup Founders Check How AI Search Platforms Describe Their Companies
-
MARS Energy Group Adds Jigar Shah to Advisory Board to Accelerate Battery Storage Growth
-
Below Deck alumnus João Franco and brother arrested after fatal Turkey fight
-
Ole Miss inquiry expands after video and monkey-noise allegations
-
General Hospital actor Randall England dies at 75
-
Argentina Inflation Rises to 2.2% in October Amid Core Price Decline
Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here
Practical partnership for AI Nose, multiple new opportunities
AI Nose to change robotics landscape with first AI smell sensing
SAN DIEGO, CA / ACCESS Newswire / March 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of smell digitization, today announced that Water Tower Research ("WTR") has published a report on the Company's strategic partnership with ugo, Inc., a leading Japanese service robotics company. The collaboration will integrate Ainos' innovative AI Nose technology into ugo's service robots, marking a milestone in digitizing olfactory sensing.
Key Highlights from the Report:
AI Nose Integration into Robots: This partnership will elevate robotic capabilities in industrial safety, public security, environmental monitoring, and healthcare. Both companies will jointly design AI Nose-enabled robots for various industries, open revenue opportunities in multiple sectors.
This is a Practical Partnership: ugo develops and commercialized next-generation avatar robots and leads Japan's service robot market share. Its robots are used in commercial buildings, data centers, factories, and public facilities, addressing Japan's workforce shortage caused by aging population. Ainos' collaboration with an established player for autonomous robots provides direct commercial access to the end-user market, rather than with a startup still in the concept stage.
Elevating Robot Functionality: ugo's robots are already equipped with advanced AI-driven features, such as collision detection sensors, AI-powered image recognition, and environmental sensors for heat mapping and humidity measurement. ugo's robots are practical and commercially viable, unlike many others that are still under development and remain costly.
The Final Sense for Robots-AI Smell is Here: While vision, sound, and touch have seen significant advancements in robotics, the sense of smell has remained an untapped sensory capability. AI Nose represents a breakthrough in olfactory sensing, becoming one of the first technologies to offer robots the ability to smell. This new capability positions Ainos at the forefront of a rapidly evolving industry.
Japan is a Key Market in a Multi-Billion Market Opportunity: Asia dominates the global robotics market, with China and Japan ranking among the top four for installed industrial robots, robotics innovation, and service robot production. Japan is a global leader in robotics, accounting for 38% of worldwide robot production in 2023. The service robot market in Japan is projected to reach $1.2 billion by 2025, compared to $9.7 billion in the U.S. and $40.6 billion globally.
New Opportunities: Ainos' partnership with ugo unlocks significant opportunities across multiple sectors, including healthcare as well as industrial and public safety. The companies expect to begin integration this year, with commercial deployment anticipated as early as 2026. This partnership is poised to accelerate innovation in smart manufacturing and safety monitoring, with far-reaching implications for the robotics industry.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name "Ainos" combines "AI" and "Nose" to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
About ugo, Inc.
ugo, Inc. is a developer of business digital transformation robots. "ugo" is a next-generation avatar robot that realizes a sustainable work style with humans and robots. By combining the advantages of both conventional simple remote-controlled robots and fully automated robots, it provides operations that fit the site. ugo was founded in 2018 and headquartered in Tokyo, Japan. For more information, visit website https://ugo.plus or its X ( @ugo_robot ).
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
[email protected]
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
O.Brown--AT